Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT
Matthias Unseld(Medical University of Vienna), Gerald W. Prager(Comprehensive Cancer Center Vienna), Clarence Veraar(Vienna General Hospital), Daniela Bianconi(Comprehensive Cancer Center Vienna), Walter Berger(Comprehensive Cancer Center Vienna), Maria Sibilia(Comprehensive Cancer Center Vienna), Fredrik Waneck(Comprehensive Cancer Center Vienna), Markus Kieler(Comprehensive Cancer Center Vienna), Christoph Zielinski(Vienna General Hospital), Robert M. Mader(Centre de Recherche en Économie et Management), Leonhard Müllauer(Hochschule Campus Wien), Fritz Wrba(University of Vienna), Lukas Baumann(Statistics Austria)
Cited by 4
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|502
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
|New England Journal of Medicine|2023|415
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
|Journal of the American Society of Nephrology|2017|302